These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 3127528

  • 1. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome.
    Golding H, Robey FA, Gates FT, Linder W, Beining PR, Hoffman T, Golding B.
    J Exp Med; 1988 Mar 01; 167(3):914-23. PubMed ID: 3127528
    [Abstract] [Full Text] [Related]

  • 2. Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals.
    Golding H, Shearer GM, Hillman K, Lucas P, Manischewitz J, Zajac RA, Clerici M, Gress RE, Boswell RN, Golding B.
    J Clin Invest; 1989 Apr 01; 83(4):1430-5. PubMed ID: 2467924
    [Abstract] [Full Text] [Related]

  • 3. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
    Klasse PJ, Pipkorn R, Blomberg J.
    Proc Natl Acad Sci U S A; 1988 Jul 01; 85(14):5225-9. PubMed ID: 2455899
    [Abstract] [Full Text] [Related]

  • 4. Common sequence in HIV 1 GP41 and HLA class II beta chains can generate crossreactive autoantibodies with immunosuppressive potential early in the course of HIV 1 infection.
    Blackburn R, Clerici M, Mann D, Lucey DR, Goedert J, Golding B, Shearer GM, Golding H.
    Adv Exp Med Biol; 1991 Jul 01; 303():63-9. PubMed ID: 1805576
    [Abstract] [Full Text] [Related]

  • 5. Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals.
    Certa U, Bannwarth W, Stüber D, Gentz R, Lanzer M, Le Grice S, Guillot F, Wendler I, Hunsmann G, Bujard H.
    EMBO J; 1986 Nov 01; 5(11):3051-6. PubMed ID: 3491755
    [Abstract] [Full Text] [Related]

  • 6. Antibodies to MHC class II peptides are present in HIV-1-positive sera.
    Zaitseva MB, Moshnikov SA, Kozhich AT, Frolova HA, Makarova OD, Pavlikov SP, Sidorovich IG, Brondz BB.
    Scand J Immunol; 1992 Mar 01; 35(3):267-73. PubMed ID: 1535985
    [Abstract] [Full Text] [Related]

  • 7. Monoclonal antibody identifies a highly conserved and immunodominant epitope of the human immunodeficiency virus transmembrane protein.
    Papsidero LD, Poiesz BJ, Montagna RA.
    Hybridoma; 1988 Apr 01; 7(2):117-28. PubMed ID: 2453451
    [Abstract] [Full Text] [Related]

  • 8. T cell recognition of HIV synthetic peptides in a natural infection.
    Schrier RD, Gnann JW, Landes R, Lockshin C, Richman D, McCutchan A, Kennedy C, Oldstone MB, Nelson JA.
    J Immunol; 1989 Feb 15; 142(4):1166-76. PubMed ID: 2783706
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I, Gulle H, Wolf HM, Maris M, Eggenbauer H, Eibl MM.
    J Exp Med; 1995 Apr 01; 181(4):1411-23. PubMed ID: 7699327
    [Abstract] [Full Text] [Related]

  • 12. Partial purification of native HIV transmembrane protein gp41: generation of polyclonal and monoclonal antibodies.
    Zweig M, Showalter SD, Bladen SV, Gilden RV, Arthur LO, Robey WG, Nara PL, Fischinger PJ.
    AIDS Res Hum Retroviruses; 1988 Feb 01; 4(1):51-62. PubMed ID: 3259140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.
    Matsumi S, Matsushita S, Yoshimura K, Javaherian K, Takatsuki K.
    AIDS Res Hum Retroviruses; 1995 Apr 01; 11(4):501-8. PubMed ID: 7632464
    [Abstract] [Full Text] [Related]

  • 15. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1.
    Modrow S, Höflacher B, Mellert W, Erfle V, Wahren B, Wolf H.
    J Acquir Immune Defic Syndr (1988); 1989 Apr 01; 2(1):21-7. PubMed ID: 2537398
    [Abstract] [Full Text] [Related]

  • 16. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, Weiss RA.
    Virology; 1988 Jul 01; 165(1):209-15. PubMed ID: 2838959
    [Abstract] [Full Text] [Related]

  • 17. Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods.
    Närvänen A, Korkolainen M, Kontio S, Suni J, Turtianen S, Partanen P, Soos J, Vaheri A, Huhtala ML.
    AIDS; 1988 Apr 01; 2(2):119-23. PubMed ID: 3132938
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV).
    Harada S, Kobayashi N, Koyanagi Y, Yamamoto N.
    Virology; 1987 Jun 01; 158(2):447-51. PubMed ID: 2438845
    [Abstract] [Full Text] [Related]

  • 20. [Mechanisms of immunodeficiency in HIV infection and ways of overcoming it].
    Brondz BD, Zaĭtseva MB, Kozhich AT, Moshnikov SA, Makarova OD, Frolova EA.
    Genetika; 1992 Jul 01; 28(7):19-26. PubMed ID: 1427054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.